Mga Batayang Estadistika
| LEI | 549300J8JGYVJJHV9C31 |
| CIK | 1459839 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to SI-BONE, Inc.
SEC Filings (Chronological Order)
Halaman ini menyediakan daftar lengkap dan kronologis dari Pengajuan SEC, tidak termasuk pengajuan kepemilikan yang kami sediakan di tempat lain.
| August 5, 2025 |
2025 Non-Employee Directors’ Compensation Policy Exhibit 10.2 SI-BONE, Inc. 2025 Non-Employee Directors’ Compensation Policy Approved by the Board of Directors Adopted on June 5, 2025 Each member of the Board of Directors (the “Board”) who is not also serving as an employee of SI-BONE, Inc. (the “Company”) or any of its subsidiaries (each such member, an “Eligible Director”) will receive the compensation described in this Non-Employee Directors’ |
|
| August 5, 2025 |
CERTAIN INFORMATION IDENTIFIED BY “[***]” HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE OF INFORMATION THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. |
|
| August 5, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark one) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38701 SI-BONE, I |
|
| August 5, 2025 |
sibn-ex104 SI-BONE, Inc. • 471 El Camino Real, Suite 101, Santa Clara, CA 95050 U.S.A. • t 408-207-0700 • f 408-557-8312 • www.SI-BONE.com July 31, 2025 Anthony J. Recupero [***] [***] Re: Your Retirement Dear Tony, This letter confirms certain terms regarding your transition from SI-BONE, Inc. (the “Company”). 1. SEPARATION DATE. You have given notice of your voluntary resignation of employment w |
|
| August 5, 2025 |
sibn-ex103 1. CONSULTING AGREEMENT THIS CONSULTING AGREEMENT (the “Agreement”) by and between SI-BONE, Inc. (“Client”) and Anthony J. Recupero, an individual (“Consultant”) (Client and Consultant together, the “Parties”) is effective as of February 16, 2026 (the “Effective Date”). 1. Engagement of Services. Consultant agrees to provide the following consulting services and other services upon requ |
|
| August 4, 2025 |
Exhibit 99.1 SI-BONE, Inc. Reports Financial Results for the Second Quarter 2025 and Raises 2025 Guidance Achieved ~22% worldwide revenue growth, positive Adjusted EBITDA and cash flow breakeven Second Quarter 2025 Financial Highlights (all comparisons are to the prior year period) •Worldwide revenue of $48.6 million, representing growth of 21.7% •U.S. revenue of $46.4 million, representing growth |
|
| August 4, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 31, 2025 SI-BONE, INC. (Exact name of registrant as specified in its charter) Delaware 001-38701 26-2216351 (State or other jurisdiction of incorporation or organization) (Commis |
|
| June 6, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 5, 2025 SI-BONE, INC. (Exact name of registrant as specified in its charter) Delaware 001-38701 26-2216351 (State or other jurisdiction of incorporation or organization) (Commiss |
|
| May 6, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark one) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38701 SI-BONE, |
|
| May 6, 2025 |
Second Amended and Restated Participation Agreement dated May 5, Second Amended and Restated Participation Agreement This Second Amended and Restated Participation Agreement (this “Second Restated Agreement”) is entered into as of this 5th day of May 2025, by and between SI-BONE, Inc. |
|
| May 5, 2025 |
Exhibit 99.1 SI-BONE, Inc. Reports Financial Results for the First Quarter 2025 and Updates 2025 Guidance Achieved ~25% worldwide revenue growth and positive adjusted EBITDA First Quarter 2025 Financial Highlights (all comparisons are to the prior year period) •Worldwide revenue of $47.3 million, representing growth of 24.9% •U.S. revenue of $44.8 million, representing growth of 26.6% •Gross margi |
|
| May 5, 2025 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 5, 2025 SI-BONE, INC. (Exact name of registrant as specified in its charter) Delaware 001-38701 26-2216351 (State or other jurisdiction of incorporation or organization) (Commissi |
|
| April 25, 2025 |
sibnproxy2025notice |
|
| April 25, 2025 |
SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| February 25, 2025 |
As filed with the U.S. Securities and Exchange Commission on February 25, 2025 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 SI-BONE, Inc. (Exact name of Registrant as specified in its charter) Delaware 26-2216351 (State or other jurisdiction of Incorporation or organization) (I.R.S. Em |
|
| February 25, 2025 |
Exhibit 19.1 Corporate Policy Insider Trading Policy Document No: CORP-0006 Revision: D Effective Date: 03/16/2023 Page 1 of 11 SI-BONE, Inc. Insider Trading Policy Approved by the Board of Directors March 21, 2017 UPDATED: MARCH 16, 2023 Introduction This policy determines acceptable transactions in the securities of SI-BONE, Inc. (the “Company”) by our employees, directors and covered consultant |
|
| February 25, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-38701 SI-BONE, Inc. ( |
|
| February 25, 2025 |
List of Subsidiaries of Registrant Exhibit 21.1 List of subsidiaries of the Registrant Subsidiary Jurisdiction SI-BONE S.R.L. Italy SI-BONE Deutschland GmbH Germany SI-BONE UK LTD United Kingdom |
|
| February 25, 2025 |
Agreement dated April 17, 2024 Exhibit 10.28 VIA ELECTRONIC DELIVERY April 17, 2024 Re: SI-BONE, Inc. Board of Directors Dear Tom: It is my sincere pleasure to invite you to join the Board of Directors (the “Board”) of SI-BONE, Inc. (the “Company”), and to serve on the Compensation Committee of the Board (the “Compensation Committee”), each contingent upon your election by the stockholders at our stockholder meeting planned for |
|
| February 25, 2025 |
Form of Financial Performance-Based Restricted Stock Unit Agreement Exhibit 10.29 SI-BONE, Inc. Restricted Stock Unit Grant Notice (2018 Equity Incentive Plan) SI-BONE, Inc. (the “Company”), pursuant to its 2018 Equity Incentive Plan (the “Plan”), hereby awards to Participant a Restricted Stock Unit Award for the number of shares of the Company’s Common Stock (“Restricted Stock Units”) set forth below (the “Award”). The Award is subject to all of the terms and con |
|
| February 25, 2025 |
Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) SI-BONE, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Share Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common Stock, $0.0001 par value per share, SI |
|
| February 24, 2025 |
Exhibit 99.1 SI-BONE, Inc. Reports Record Financial Results for the Fourth Quarter 2024 and Issues 2025 Guidance Achieves 26% worldwide revenue growth and positive adjusted EBITDA in Fourth Quarter 2024 SANTA CLARA, Calif. February 24, 2025 - SI-BONE, Inc. (Nasdaq:SIBN), a medical device company dedicated to solving sacropelvic disorders, today reported financial results for the fourth quarter and |
|
| February 24, 2025 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 24, 2025 SI-BONE, INC. (Exact name of registrant as specified in its charter) Delaware 001-38701 26-2216351 (State or other jurisdiction of incorporation or organization) (Co |
|
| January 13, 2025 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 13, 2025 SI-BONE, INC. (Exact name of registrant as specified in its charter) Delaware 001-38701 26-2216351 (State or other jurisdiction of incorporation or organization) (Com |
|
| January 13, 2025 |
Exhibit 99.1 SI-BONE Announces Preliminary Revenue for the Fourth Quarter and Full Year 2024 Fourth Quarter 2024 worldwide revenue of ~$48.8 to $49.0 million representing growth of ~26% Achieved adjusted EBITDA profitability in the fourth quarter SANTA CLARA, Calif., January 13, 2025 – SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving sacropelvic disorders, today announce |
|
| November 14, 2024 |
SC 13G 1 sibn-sc13ga111424.htm AMENDMENT TO FORM SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934* (Amendment) SI-Bone, Inc (Name of Issuer) Common Stock, $0.01 par value (Title of Class of Securities) 825704109 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement) Check the app |
|
| November 14, 2024 |
SIBN / SI-BONE, Inc. / ORBIMED CAPITAL LLC - AMENDMENT NO. 3 Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| November 14, 2024 |
EX-99.A 2 ex99-a.htm JOINT FILING AGREEMENT CUSIP No . 825704109 Page 7 of 7 Exhibit A JOINT FILING AGREEMENT The Undersigned agree that the statement on Schedule 13G with respect to the common stock of SI-Bone, Inc dated as of November 14, 2024 is, and any amendment thereto signed by each of the undersigned shall be, filed on behalf of each of them pursuant to and in accordance with the provision |
|
| November 12, 2024 |
hird Amendment to Loan and Security Agreement, dated November 8, 2024, between Exhibit 10.2 CERTAIN INFORMATION IDENTIFIED BY “[***]” HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE OF INFORMATION THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. THIRD AMENDMENT TO LOAN AND SECURITY AGREEMENT This Third Amendment to Loan and Security Agreement (this “Amendment”) is entered into as of August 8, 2024, by and between (i) SILICON VALLEY BA |
|
| November 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark one) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38701 SI-BO |
|
| November 12, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 12, 2024 SI-BONE, INC. (Exact name of registrant as specified in its charter) Delaware 001-38701 26-2216351 (State or other jurisdiction of incorporation or organization) (Co |
|
| November 12, 2024 |
Exhibit 99.1 SI-BONE, Inc. Reports Financial Results for the Third Quarter 2024 and Updates Guidance Expects to achieve positive Adjusted EBITDA in Fourth Quarter 2024 SANTA CLARA, Calif. November, 12 2024 - SI-BONE, Inc. (Nasdaq:SIBN), a medical device company dedicated to solving sacropelvic disorders, today reported financial results for the quarter ended September 30, 2024. Third Quarter 2024 |
|
| November 8, 2024 |
SIBN / SI-BONE, Inc. / AMERICAN CENTURY INVESTMENT MANAGEMENT INC - SC 13G Passive Investment SC 13G 1 si-boneinc13g.htm SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. ) * SI-BONE, INC. (Name of Issuer) COMMON STOCK (Title of Class of Securities) 825704109 (CUSIP Number) SEPTEMBER 30, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the ru |
|
| August 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark one) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38701 SI-BONE, I |
|
| August 5, 2024 |
Exhibit 99.1 SI-BONE, Inc. Reports Financial Results for the Second Quarter 2024 Increases 2024 revenue guidance to $165 million - $167 million Expects to achieve positive Adjusted EBITDA in Fourth Quarter 2024 SANTA CLARA, Calif. August 5, 2024 - SI-BONE, Inc. (Nasdaq:SIBN), a medical device company dedicated to solving sacropelvic disorders, today reported financial results for the quarter ended |
|
| August 5, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 4, 2024 SI-BONE, INC. (Exact name of registrant as specified in its charter) Delaware 001-38701 26-2216351 (State or other jurisdiction of incorporation or organization) (Commi |
|
| July 19, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported):July 18, 2024 SI-BONE, INC. (Exact name of registrant as specified in its charter) Delaware 001-38701 26-2216351 (State or other jurisdiction of incorporation or organization) (Commiss |
|
| July 19, 2024 |
Exhibit 10.1 UNIVERSITY STATION SECOND AMENDMENT TO LEASE (SI-BONE INC.) THIS SECOND AMENDMENT TO LEASE (this “Amendment”) is made as of July 18, 2024, by and between BIXBY SPE FINANCE 11, LLC, a Delaware limited liability company (“Landlord”), and SI-BONE INC., a Delaware corporation (“Tenant”). RECITALS A. Landlord and Tenant are parties to that certain Office Lease Agreement (the “Original Leas |
|
| June 26, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 25, 2024 SI-BONE, INC. (Exact name of registrant as specified in its charter) Delaware 001-38701 26-2216351 (State or other jurisdiction of incorporation or organization) (Commis |
|
| June 26, 2024 |
Amendment to Amended and Restated Certificate of Incorporation Exhibit 3.1 CERTIFICATE OF AMENDMENT OF AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF SI-BONE, INC. SI-BONE, Inc., a corporation duly organized and existing under the laws of the State of Delaware (the “Corporation”) pursuant to Section 242 of the General Corporation Law of the State of Delaware (the “DGCL”), hereby certifies as follows: First: The name of the Corporation is SI-BONE, Inc. T |
|
| May 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark one) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38701 SI-BONE, |
|
| May 6, 2024 |
Exhibit 99.1 SI-BONE, Inc. Reports Financial Results for the First Quarter 2024 Annual guidance increased to $164 million - $166 million, implying annual growth of ~18% - 20% SANTA CLARA, Calif. May 6, 2024 - SI-BONE, Inc. (Nasdaq:SIBN), a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, today reported financial results for the quarter ended March 3 |
|
| May 6, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 6, 2024 SI-BONE, INC. (Exact name of registrant as specified in its charter) Delaware 001-38701 26-2216351 (State or other jurisdiction of incorporation or organization) (Commissi |
|
| April 29, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) Filed by the Registrant þ Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ¨ Defini |
|
| April 29, 2024 |
SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| April 18, 2024 |
SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| February 27, 2024 |
2023 Recoupment (Clawback) Policy Exhibit 97.1 SI-BONE, INC. Incentive Compensation Recoupment Policy (Effective October 2, 2023) 1.Introduction The Board of Directors (the “Board”) of SI-BONE, Inc., a Delaware corporation (the “Company”), has determined that it is in the best interests of the Company and its stockholders to adopt this Incentive Compensation Recoupment Policy (this “Policy”) providing for the Company’s recoupment |
|
| February 27, 2024 |
Manufacture and Supply Agreement, dated February 23, 2024, between CONFIDENTIAL AND PROPRIETARY EXHIBIT 10.27 CERTAIN INFORMATION IDENTIFIED BY “[***]” HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE OF INFORMATION THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. MANUFACTURE AND SUPPLY AGREEMENT THIS MANUFACTURE AND SUPPLY AGREEMENT (“Agreement”) is entered into as of February 23, 2024 (the “Effective Date”), between SI-BO |
|
| February 27, 2024 |
Second Amendment to Loan and Security Agreement, dated January EXHIBIT 10.26 CERTAIN INFORMATION IDENTIFIED BY “[***]” HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE OF INFORMATION THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. SECOND AMENDMENT TO LOAN AND SECURITY AGREEMENT This SECOND AMENDMENT TO LOAN AND SECURITY AGREEMENT (this “Agreement”) is entered into as of January 25, 2024, by and between SILICON VALLEY B |
|
| February 27, 2024 |
As filed with the U.S. Securities and Exchange Commission on February 27, 2024 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 SI-BONE, Inc. (Exact name of Registrant as specified in its charter) Delaware 26-2216351 (State or other jurisdiction of Incorporation or organization) (I.R.S. Em |
|
| February 27, 2024 |
List of Subsidiaries of Registrant Exhibit 21.1 List of subsidiaries of the Registrant Subsidiary Jurisdiction SI-BONE S.R.L. Italy SI-BONE Deutschland GmbH Germany SI-BONE UK LTD United Kingdom |
|
| February 27, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-38701 SI-BONE, Inc. ( |
|
| February 27, 2024 |
Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) SI-BONE, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Share Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common Stock, $0.0001 par value per share, SI |
|
| February 26, 2024 |
Exhibit 99.1 SI-BONE, Inc. Reports Record Fourth Quarter and Full Year 2023 Financial Results and Issues 2024 Guidance SANTA CLARA, Calif. February 26, 2024 - SI-BONE, Inc. (Nasdaq:SIBN), a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, today reported financial results for the fourth quarter and full year ended December 31, 2023. Fourth Quarter 20 |
|
| February 26, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 26, 2024 SI-BONE, INC. (Exact name of registrant as specified in its charter) Delaware 001-38701 26-2216351 (State or other jurisdiction of incorporation or organization) (Co |
|
| February 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934* SI-Bone, Inc (Name of Issuer) Common Stock, $0.01 par value (Title of Class of Securities) 825704109 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is |
|
| February 14, 2024 |
SIBN / SI-BONE, Inc. / ORBIMED ADVISORS LLC - AMENDMENT NO. 2 Passive Investment SC 13G/A 1 ss3005754sc13ga.htm AMENDMENT NO. 2 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* SI-BONE, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 825704109 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check |
|
| February 14, 2024 |
EX-99.A 2 ss3005754ex99a.htm JOINT FILING AGREEMENT EXHIBIT A JOINT FILING AGREEMENT The undersigned hereby agree that this Amendment No. 2 to the Statement on Schedule 13G, dated December 31, 2023 (this “Schedule 13G”), with respect to the Common Stock, $0.0001 par value per share, of SI-BONE, Inc. is filed on behalf of each of us pursuant to and in accordance with the provisions of Rule 13d-1(k) |
|
| February 13, 2024 |
SIBN / SI-BONE, Inc. / VANGUARD GROUP INC - SCHEDULE 13G Passive Investment SC 13G 1 tv01917-siboneinc.htm SCHEDULE 13G SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 Name of issuer: SI-BONE Inc Title of Class of Securities: Common Stock CUSIP Number: 825704109 Date of Event Which Requires Filing of this Statement: December 29, 2023 Check the appropriate box to designate the rule pursuant to which this Sche |
|
| February 9, 2024 |
SIBN / SI-BONE, Inc. / BROWN ADVISORY INC - BROWN ADVISORY INC Passive Investment SC 13G/A 1 sibna3.htm BROWN ADVISORY INC UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3)* SI-BONE, Inc. (Name of Issuer) (Title of Class of Securities) 825704109 (CUSIP Number) December 31, 2023 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule purs |
|
| January 22, 2024 |
SIBN / SI-BONE, Inc. / INTEGRATED CORE STRATEGIES (US) LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (AMENDMENT NO. 1) SI-BONE, INC. (Name of Issuer) COMMON STOCK, PAR VALUE $0.0001 PER SHARE (Title of Class of Securities) 825704109 (CUSIP Number) DECEMBER 31, 2023 (Date of event which requires filing of this statement) Check the appropriate box to designate the rule purs |
|
| January 8, 2024 |
si-bonecorporateoverview SI-BONE Corporate Overview January 2024 This presentation contains “ forward-looking statements,” which are statements related to events, results, activities or developments that SI-BONE expects, believes or anticipates will or may occur in the future. |
|
| January 8, 2024 |
Exhibit 99.1 SI-BONE Announces Preliminary Revenue for the Fourth Quarter and Full Year 2023 Fiscal Year 2023 revenue of $138.5 - $138.7 million representing growth of over 30% SANTA CLARA, Calif., January 8, 2024 – SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, today announced its preliminary and unaudited revenue |
|
| January 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 8, 2024 SI-BONE, INC. (Exact name of registrant as specified in its charter) Delaware 001-38701 26-2216351 (State or other jurisdiction of incorporation or organization) (Comm |
|
| November 7, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark one) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38701 SI-BO |
|
| November 6, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 6, 2023 SI-BONE, INC. (Exact name of registrant as specified in its charter) Delaware 001-38701 26-2216351 (State or other jurisdiction of incorporation or organization) (Com |
|
| November 6, 2023 |
Exhibit 99.1 SI-BONE, Inc. Reports Record Financial Results for the Third Quarter 2023 and Raises Annual Guidance Annual guidance increased to $136 million - $137 million, implying annual growth of 28%-29% SANTA CLARA, Calif. November 6, 2023 - SI-BONE, Inc. (Nasdaq:SIBN), a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, today reported financial r |
|
| September 20, 2023 |
Second Amended and Restated Bylaws Exhibit 3.1 SECOND AMENDED AND RESTATED BYLAWS OF SI-BONE, INC. (A DELAWARE CORPORATION) Table of Contents Page ARTICLE I OFFICES 1 Section 1. Registered Office 1 Section 2. Other Offices 1 ARTICLE II CORPORATE SEAL 1 Section 3. Corporate Seal 1 ARTICLE III STOCKHOLDERS’ MEETINGS 1 Section 4. Place of Meetings 1 Section 5. Annual Meetings 1 Section 6. Special Meetings 6 Section 7. Notice of Meetin |
|
| September 20, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): September 19, 2023 SI-BONE, INC. (Exact name of registrant as specified in its charter) Delaware 001-38701 26-2216351 (State or other jurisdiction of incorporation or organization) (C |
|
| August 8, 2023 |
2023 Non-Employee Directors' Compensation Policy Exhibit 10.1 SI-BONE, Inc. 2023 Non-Employee Directors’ Compensation Policy Approved by the Board of Directors June 9, 2023 Each member of the Board of Directors (the “Board”) who is not also serving as an employee of SI-BONE, Inc. (the “Company”) or any of its subsidiaries (each such member, an “Eligible Director”) will receive the compensation described in this Non-Employee Directors’ Compensati |
|
| August 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark one) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38701 SI-BONE, I |
|
| August 7, 2023 |
Exhibit 99.1 SI-BONE, Inc. Reports Financial Results for the Second Quarter 2023 and Increases Annual Guidance Annual guidance increased to $132 million - $134 million, implying annual growth of 24%-26% SANTA CLARA, Calif. August 7, 2023 - SI-BONE, Inc. (Nasdaq:SIBN), a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, today reported financial result |
|
| August 7, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 7, 2023 SI-BONE, INC. (Exact name of registrant as specified in its charter) Delaware 001-38701 26-2216351 (State or other jurisdiction of incorporation or organization) (Commi |
|
| June 12, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 9, 2023 SI-BONE, INC. (Exact name of registrant as specified in its charter) Delaware 001-38701 26-2216351 (State or other jurisdiction of incorporation or organization) (Commiss |
|
| May 11, 2023 |
SIBN / SI-BONE Inc / INTEGRATED CORE STRATEGIES (US) LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 SI-BONE, INC. (Name of Issuer) COMMON STOCK, PAR VALUE $0.0001 PER SHARE (Title of Class of Securities) 825704109 (CUSIP Number) MAY 5, 2023 (Date of event which requires filing of this statement) Check the appropriate box to designate the rule pursuant to which this Sched |
|
| May 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 4, 2023 SI-BONE, INC. (Exact name of registrant as specified in its charter) Delaware 001-38701 26-2216351 (State or other jurisdiction of incorporation or organization) (Commissi |
|
| May 8, 2023 |
Prospectus Supplement (To Prospectus dated May 4, 2023) 3,775,000 Shares Common Stock Filed Pursuant to Rule 424(b)(5) Registration No. 333-271635 Prospectus Supplement (To Prospectus dated May 4, 2023) 3,775,000 Shares Common Stock We, SI-BONE, Inc., are offering 3,502,247 shares of our common stock, and the selling stockholder named in this prospectus supplement is offering 272,753 shares of our common stock. Our common stock is listed on the Nasdaq Global Market under the symbol |
|
| May 8, 2023 |
Exhibit 107 Calculation of Filing Fee Table 424(b)(5) (Form Type) SI-BONE, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Share Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee (1) Carr |
|
| May 8, 2023 |
Underwriting Agreement, dated May 4, 2023 Exhibit 1.1 Execution Version 3,775,000 Shares SI-BONE, INC. COMMON STOCK (PAR VALUE $0.0001 PER SHARE) UNDERWRITING AGREEMENT May 4, 2023 |US-DOCS\140511620.6|| May 4, 2023 BofA Securities, Inc. Morgan Stanley & Co. LLC Jefferies LLC c/o BofA Securities, Inc. One Bryant Park New York, New York 10036 c/o Morgan Stanley & Co. LLC 1585 Broadway New York, NY 10036 c/o Jefferies LLC 520 Madison Avenue |
|
| May 4, 2023 |
Filed Pursuant to Rule 424(b)(5) Registration No. 333-271635 The information in this preliminary prospectus supplement is not complete and may be changed. A registration statement relating to these securities has been filed with the Securities and Exchange Commission and is effective. This preliminary prospectus supplement and accompanying prospectus are not an offer to sell these securities, and |
|
| May 4, 2023 |
As filed with the Securities and Exchange Commission on May 4, 2023 Registration No. |
|
| May 4, 2023 |
Form of Common Stock Warrant Agreement and Warrant Certificate Exhibit 4.6 SI-BONE, Inc. and , As Warrant Agent Form Of Common Stock Warrant Agreement Dated As Of SI-BONE, INC. FORM OF COMMON STOCK WARRANT AGREEMENT This Common Stock Warrant Agreement (this “Agreement”), dated as of [●], between, SI-BONE, Inc., a Delaware corporation (the “Company”) and [●], a [corporation] [national banking association] organized and existing under the laws of [●] and having |
|
| May 4, 2023 |
Exhibit 107 Calculation of Filing Fee Table Form S-3 (Form Type) SI-BONE, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Share Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry For |
|
| May 4, 2023 |
Form of Preferred Stock Warrant Agreement and Warrant Certificate Exhibit 4.7 SI-BONE, Inc. and , As Warrant Agent Form Of Preferred Stock Warrant Agreement Dated As Of SI-BONE, INC. FORM OF PREFERRED STOCK WARRANT AGREEMENT This Preferred Stock Warrant Agreement (this “Agreement”), dated as of [●], between SI-BONE, Inc., a Delaware corporation (the “Company”) and [●], a [corporation] [national banking association] organized and existing under the laws of [●] an |
|
| May 2, 2023 |
Letter Agreement, dated March 24, 2023 between EXHIBIT 10.2 March 24, 2023 Letter Agreement Reference is made to the Loan and Security Agreement dated as of August 12, 2021 by and between Silicon Valley Bank, now known as Silicon Valley Bridge Bank, N.A. (“Bank”) and SI-BONE, Inc., a Delaware corporation (“Borrower”) (as amended modified, supplemented and/or restated from time to time, including, without limitation, pursuant to that certain Fi |
|
| May 2, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark one) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38701 SI-BONE, |
|
| May 2, 2023 |
EXHIBIT 10.1 CERTAIN INFORMATION IDENTIFIED BY “[***]” HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE OF INFORMATION THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. FIRST AMENDMENT TO LOAN AND SECURITY AGREEMENT This First Amendment to Loan and Security Agreement (this “Amendment”) is entered into as of January 6, 2023, by and between (i) SILICON VALLEY B |
|
| May 1, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 1, 2023 SI-BONE, INC. (Exact name of registrant as specified in its charter) Delaware 001-38701 26-2216351 (State or other jurisdiction of incorporation or organization) (Commissi |
|
| May 1, 2023 |
Exhibit 99.1 SI-BONE, Inc. Reports Financial Results for the First Quarter 2023 and Increases Annual Guidance Annual guidance increased to $128 million - $131 million, implying annual growth of 20%-23% SANTA CLARA, Calif. May 1, 2023 - SI-BONE, Inc. (Nasdaq:SIBN), a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, today reported financial results fo |
|
| April 28, 2023 |
SI-BONE, Inc. 471 El Camino Real, Suite 101 Santa Clara, California 95050 SI-BONE, Inc. 471 El Camino Real, Suite 101 Santa Clara, California 95050 April 28, 2023 Via Email and Edgar U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Mail Stop 3720 Washington, D.C. 20549 Attn: Michael Fay or Brian Cascio, Accounting Branch Chief Re: SI-BONE, Inc. Form 10-K for the fiscal year ended December 31, 2022 Filed March 2, 2023 Response da |
|
| April 25, 2023 |
sibn10-kasfiled UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-38701 |
|
| April 24, 2023 |
DEFA14A 1 sibn-defa14atofile.htm DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) Filed by the Registrant þ Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (a |
|
| April 21, 2023 |
SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| April 14, 2023 |
SI-BONE, Inc. 471 El Camino Real, Suite 101 Santa Clara, California 95050 April 14, 2023 Via Email and Edgar U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Mail Stop 3720 Washington, D.C. 20549 Attn: Michael Fay or Brian Cascio, Accounting Branch Chief RE: SI-BONE, Inc. Form 10-K For the fiscal year ended December 31, 2022 Filed March 2, 2023 File No. 00 |
|
| March 2, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-38701 SI-BONE, Inc. ( |
|
| March 2, 2023 |
As filed with the U.S. Securities and Exchange Commission on March 2, 2023 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 SI-BONE, Inc. (Exact name of Registrant as specified in its charter) Delaware 26-2216351 (State or other jurisdiction of Incorporation or organization) (I.R.S. Employ |
|
| March 2, 2023 |
List of Subsidiaries of Registrant Exhibit 21.1 List of subsidiaries of the Registrant Subsidiary Jurisdiction SI-BONE S.R.L. Italy SI-BONE Deutschland GmbH Germany SI-BONE UK LTD United Kingdom |
|
| March 2, 2023 |
Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) SI-BONE, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Share Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common Stock, $0.0001 par value per share, SI |
|
| March 2, 2023 |
confidentialmarkupsvb-x EXHIBIT 10.29 CERTAIN INFORMATION IDENTIFIED BY “[***]” HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE OF INFORMATION THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. FIRST AMENDMENT TO LOAN AND SECURITY AGREEMENT This First Amendment to Loan and Security Agreement (this “Amendment”) is entered into as of January 6, 2023, by and bet |
|
| March 2, 2023 |
2022 Non-Employee Directors' Compensation Policy Exhibit 10.18 SI-BONE, Inc. 2022 Non-Employee Directors’ Compensation Policy Approved by the Board of Directors December 1, 2022 Each member of the Board of Directors (the “Board”) who is not also serving as an employee of SI-BONE, Inc. (the “Company”) or any of its subsidiaries (each such member, an “Eligible Director”) will receive the compensation described in this Non-Employee Directors’ Compe |
|
| February 27, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 27, 2023 SI-BONE, INC. (Exact name of registrant as specified in its charter) Delaware 001-38701 26-2216351 (State or other jurisdiction of incorporation or organization) (Co |
|
| February 27, 2023 |
SI-BONE, Inc. Reports Fourth Quarter and Full Year 2022 Financial Results and Issues 2023 Guidance Exhibit 99.1 SI-BONE, Inc. Reports Fourth Quarter and Full Year 2022 Financial Results and Issues 2023 Guidance SANTA CLARA, Calif. February 27, 2023 - SI-BONE, Inc. (Nasdaq:SIBN), a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, today reported financial results for the fourth quarter and full year ended December 31, 2022. Recent Financial Highlig |
|
| February 14, 2023 |
SC 13G 1 sibn-sc13g123122.htm SCHEDULE FILED TO REPORT ACQUISITION OF BENEFICIAL OWNERSHIP UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934* SI-Bone, Inc (Name of Issuer) Common Stock, $0.01 par value (Title of Class of Securities) 825704109 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this St |
|
| February 14, 2023 |
SIBN / SI-Bone Inc / ORBIMED ADVISORS LLC - AMENDMENT NO. 1 Passive Investment SC 13G/A 1 ss1758619sc13ga.htm AMENDMENT NO. 1 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G (Amendment No. 1)* Under the Securities Exchange Act of 1934 SI-BONE, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 825704109 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) Check |
|
| February 14, 2023 |
EX-99 2 ss1758619ex99a.htm JOINT FILING AGREEMENT EXHIBIT A JOINT FILING AGREEMENT The undersigned hereby agree that the Statement on this Schedule 13G dated December 31, 2022 (the “Schedule 13G”), with respect to the Common Stock, $0.0001 par value per share, of SI-BONE, Inc. is filed on behalf of each of us pursuant to and in accordance with the provisions of Rule 13d-1(k) under the Securities E |
|
| February 9, 2023 |
SIBN / SI-Bone Inc / BROWN ADVISORY INC - BROWN ADVISORY INCORPORATED Passive Investment SC 13G/A 1 sibna220923.htm BROWN ADVISORY INCORPORATED UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* SI-BONE, Inc. (Name of Issuer) (Title of Class of Securities) 825704109 (CUSIP Number) December 31, 2022 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate |
|
| January 9, 2023 |
1 Corporate Overview January 2023 Safe Harbor Statement This presentation contains “forward-looking statements,” which are statements related to events, results, activities or developments that SI-BONE expects, believes or anticipates will or may occur in the future. |
|
| January 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 6, 2023 SI-BONE, INC. (Exact name of registrant as specified in its charter) Delaware 001-38701 26-2216351 (State or other jurisdiction of incorporation or organization) (Comm |
|
| January 9, 2023 |
Exhibit 99.1 SI-BONE Announces Preliminary Revenue for the Fourth Quarter and Full Year 2022 Fourth Quarter revenue of $31.7 - $31.9 million representing growth of approximately 26% Fiscal Year 2022 revenue of $106.1 - $106.3 million representing growth of approximately 18% SANTA CLARA, Calif., January 9, 2023 – SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving musculoske |
|
| November 8, 2022 |
Form of Performance-Based Restricted Unit Agreement Exhibit 10.2 SI-BONE, Inc. Restricted Stock Unit Grant Notice (2018 Equity Incentive Plan) SI-BONE, Inc. (the ?Company?), pursuant to its 2018 Equity Incentive Plan (the ?Plan?), hereby awards to Participant a Restricted Stock Unit Award for the number of shares of the Company?s Common Stock (?Restricted Stock Units?) set forth below (the ?Award?). The Award is subject to all of the terms and cond |
|
| November 8, 2022 |
Form of Restricted Stock Unit Grant Notice and Award Agreement Exhibit 10.1 SI-BONE, Inc. Restricted Stock Unit Grant Notice (2018 Equity Incentive Plan) SI-BONE, Inc. (the ?Company?), pursuant to its 2018 Equity Incentive Plan (the ?Plan?), hereby awards to Participant a Restricted Stock Unit Award for the number of shares of the Company?s Common Stock (?Restricted Stock Units?) set forth below (the ?Award?). The Award is subject to all of the terms and cond |
|
| November 8, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark one) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38701 SI-BO |
|
| November 7, 2022 |
SI-BONE, Inc. Reports Financial Results for the Third Quarter 2022 and Updates Guidance Exhibit 99.1 SI-BONE, Inc. Reports Financial Results for the Third Quarter 2022 and Updates Guidance SANTA CLARA, Calif. November 7, 2022 - SI-BONE, Inc. (Nasdaq:SIBN), a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, today reported financial results for the quarter ended September 30, 2022. Recent Highlights ?Record worldwide revenue of $26.4 mil |
|
| November 7, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 7, 2022 SI-BONE, INC. (Exact name of registrant as specified in its charter) Delaware 001-38701 26-2216351 (State or other jurisdiction of incorporation or organization) (Com |
|
| August 9, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark one) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38701 SI-BONE, I |
|
| August 8, 2022 |
SI-BONE, Inc. Reports Financial Results for the Second Quarter 2022 Exhibit 99.1 SI-BONE, Inc. Reports Financial Results for the Second Quarter 2022 SANTA CLARA, Calif. August 8, 2022 - SI-BONE, Inc. (Nasdaq:SIBN), a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, today reported financial results for the quarter ended June 30, 2022. Recent Highlights ?Record worldwide revenue of $25.6 million for the second quarter |
|
| August 8, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 8, 2022 SI-BONE, INC. (Exact name of registrant as specified in its charter) Delaware 001-38701 26-2216351 (State or other jurisdiction of incorporation or organization) (Commi |
|
| June 17, 2022 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported):June 16, 2022 SI-BONE, INC. (Exact name of registrant as specified in its charter) Delaware 001-38701 26-2216351 (State or other jurisdiction of incorporation or organization) (Commiss |
|
| June 6, 2022 |
SIBN / SI-Bone Inc / BROWN ADVISORY INC - BROWN ADVISORY INCORPORATED Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* SI-BONE, Inc. (Name of Issuer) (Title of Class of Securities) 825704109 (CUSIP Number) May 31, 2022 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [X] Rule |
|
| May 10, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark one) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38701 SI-BONE, |
|
| May 9, 2022 |
SI-BONE, Inc. Reports First Quarter 2022 Financial Results Exhibit 99.1 SI-BONE, Inc. Reports First Quarter 2022 Financial Results SANTA CLARA, Calif. May 9, 2022 - SI-BONE, Inc. (Nasdaq:SIBN), a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, today reported financial results for the quarter ended March 31, 2022. Recent Highlights ?Worldwide revenue of $22.4 million for the first quarter 2022, representing |
|
| May 9, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 9, 2022 SI-BONE, INC. (Exact name of registrant as specified in its charter) Delaware 001-38701 26-2216351 (State or other jurisdiction of incorporation or organization) (Commissi |
|
| April 22, 2022 |
SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| March 1, 2022 |
As filed with the U.S. Securities and Exchange Commission on March 1, 2022 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 SI-BONE, Inc. (Exact name of Registrant as specified in its charter) Delaware 26-2216351 (State or other jurisdiction of Incorporation or organization) (I.R.S. Employ |
|
| March 1, 2022 |
Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) SI-BONE, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Share Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common Stock, $0.0001 par value per share, SI |
|
| March 1, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-38701 SI-BONE, Inc. ( |
|
| March 1, 2022 |
List of Subsidiaries of Registrant Exhibit 21.1 List of subsidiaries of the Registrant Subsidiary Jurisdiction SI-BONE S.R.L. Italy SI-BONE Deutschland GmbH Germany SI-BONE UK LTD United Kingdom |
|
| February 28, 2022 |
Exhibit 99.1 SI-BONE, Inc. Reports Fourth Quarter and Full Year 2021 Financial Results and Issues 2022 Revenue Guidance SANTA CLARA, Calif. February 28, 2022 - SI-BONE, Inc. (Nasdaq:SIBN), a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, today reported financial results for the quarter and full year ended December 31, 2021. Recent Highlights ?Worl |
|
| February 28, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 28, 2022 SI-BONE, INC. (Exact name of registrant as specified in its charter) Delaware 001-38701 26-2216351 (State or other jurisdiction of incorporation or organization) (Co |
|
| February 14, 2022 |
SIBN / SI-Bone Inc / GILDER GAGNON HOWE & CO LLC - SCHEDULE 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (RULE 13d - 102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO 13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2 (Amendment No. 1)* SI-BONE, Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 825704109 (CUSIP Number) December 31, 2021 (Date of Event whi |
|
| February 11, 2022 |
SIBN / SI-Bone Inc / ORBIMED CAPITAL LLC - SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 SI-BONE, Inc. |
|
| February 11, 2022 |
SIBN / SI-Bone Inc / GILDER GAGNON HOWE & CO LLC - SC 13G Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (RULE 13d - 102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO 13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2 SI-BONE, Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 825704109 (CUSIP Number) December 31, 2020 (Date of Event which Requires Filing |
|
| February 8, 2022 |
SIBN / SI-Bone Inc / INTEGRATED CORE STRATEGIES (US) LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (AMENDMENT NO. 1) SI-BONE, INC. (Name of Issuer) COMMON STOCK, PAR VALUE $0.0001 PER SHARE (Title of Class of Securities) 825704109 (CUSIP Number) DECEMBER 31, 2021 (Date of event which requires filing of this statement) Check the appropriate box to designate the rule purs |
|
| February 7, 2022 |
SIBN / SI-Bone Inc / BROWN ADVISORY INC - BROWN ADVISORY INCORPORATED Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 SI-BONE, Inc. (Name of Issuer) (Title of Class of Securities) 825704109 (CUSIP Number) December 31, 2021 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [X] Rule 13d-1(b) [ ] |
|
| January 10, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 6, 2022 SI-BONE, INC. (Exact name of registrant as specified in its charter) Delaware 001-38701 26-2216351 (State or other jurisdiction of incorporation or organization) (Comm |
|
| January 10, 2022 |
1 Corporate Overview January 2022 Safe Harbor Statement This presentation contains ?forward-looking statements,? which are statements related to events, results, activities or developments that SI-BONE expects, believes or anticipates will or may occur in the future. |
|
| January 10, 2022 |
Form of Performance-Based Restricted Stock Unit Agreement 1. SI-BONE, INC. RESTRICTED STOCK UNIT GRANT NOTICE (2018 EQUITY INCENTIVE PLAN) SI-BONE, Inc. (the ?Company?), pursuant to its 2018 Equity Incentive Plan (the ?Plan?), hereby awards to Participant a Restricted Stock Unit Award for the number of shares of the Company?s Common Stock (?Restricted Stock Units?) set forth below (the ?Award?). The Award is subject to all of the terms and conditions as |
|
| January 10, 2022 |
Exhibit 99.1 SI-BONE Announces Revenue for the Fourth Quarter and Full Year 2021 Preliminary 2021 revenue of $89.8-90.1 million represents growth of 22%-23% SANTA CLARA, Calif., January 10, 2022 ? SI-BONE, Inc. (Nasdaq: SIBN) (?SI-BONE? or the ?Company?), a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, today announced its preliminary and unaudite |
|
| November 9, 2021 |
Loan and Security Agreement, dated August 12, 2021, between SI-BONE, Inc. and Silicon Valley Bank EXHIBIT 10.1 LOAN AND SECURITY AGREEMENT This LOAN AND SECURITY AGREEMENT (this ?Agreement?) is dated as of the Effective Date between SILICON VALLEY BANK, a California corporation (?Bank?), and the borrower listed on Schedule I hereto (?Borrower?). The parties agree as follows: 1.LOAN AND TERMS OF PAYMENT 1.1Term Loan Advance. (a)Availability. Subject to the terms and conditions of this Agreement |
|
| November 9, 2021 |
EXHIBIT 10.2 SECOND AMENDMENT TO OFFER LETTER AGREEMENT AND SEVERANCE PLAN PARTICIPATION AGREEMENT This Second Amendment (this ?Amendment?) to the Offer Letter Agreement by and between SI-BONE, Inc. (the ?Company?) and Jeffrey Dunn (the ?Executive?), dated as of the 15th day of December, 2009 (the ?Letter Agreement?) and the Participation Agreement (the ?Participation Agreement?) under the SI-BONE |
|
| November 9, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark one) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38701 SI-BO |
|
| November 8, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 8, 2021 SI-BONE, INC. (Exact name of registrant as specified in its charter) Delaware 001-38701 26-2216351 (State or other jurisdiction of incorporation or organization) (Com |
|
| November 8, 2021 |
SI-BONE, Inc. Reports Third Quarter 2021 Financial Results and Updates 2021 Financial Guidance Exhibit 99.1 SI-BONE, Inc. Reports Third Quarter 2021 Financial Results and Updates 2021 Financial Guidance SANTA CLARA, Calif. November 8, 2021 - SI-BONE, Inc. (Nasdaq:SIBN), a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, today reported financial results for the quarter ended September 30, 2021. Recent Highlights ?Record worldwide revenue of $2 |
|
| September 28, 2021 |
SIBN / SI-Bone Inc / INTEGRATED CORE STRATEGIES (US) LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 SI-BONE, INC. (Name of Issuer) COMMON STOCK, PAR VALUE $0.0001 PER SHARE (Title of Class of Securities) 825704109 (CUSIP Number) SEPTEMBER 22, 2021 (Date of event which requires filing of this statement) Check the appropriate box to designate the rule pursuant to which thi |
|
| August 13, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported):August 12, 2021 SI-BONE, INC. (Exact name of registrant as specified in its charter) Delaware 001-38701 26-2216351 (State or other jurisdiction of incorporation or organization) (Commi |
|
| August 4, 2021 |
CONFIDENTIAL & PROPRIETARY Exhibit 10.4 AMENDED AND RESTATED MANUFACTURING, QUALITY AND SUPPLY AGREEMENT THIS AMENDED AND RESTATED MANUFACTURING, QUALITY AND SUPPLY AGREEMENT (?Agreement?) is entered into as of June 11, 2021 (the ?Effective Date?), between SI-BONE, Inc., a Delaware corporation having an address of 471 El Camino Real, Suite 101, Santa Clara, CA 95050 (including its Affiliates, ?SI- |
|
| August 4, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark one) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38701 SI-BONE, I |
|
| August 2, 2021 |
Exhibit 99.1 SI-BONE, Inc. Reports Second Quarter 2021 Financial Results and Announces Exclusive Coverage from Anthem Record Second Quarter 2021 Worldwide Revenue of $22.2 million SANTA CLARA, Calif. August 2, 2021 - SI-BONE, Inc. (Nasdaq:SIBN), a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, today reported financial results for the quarter ended |
|
| August 2, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 2, 2021 SI-BONE, INC. (Exact name of registrant as specified in its charter) Delaware 001-38701 26-2216351 (State or other jurisdiction of incorporation or organization) (Commi |
|
| June 11, 2021 |
Entry into a Material Definitive Agreement, Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 10, 2021 SI-BONE, INC. (Exact name of registrant as specified in its charter) Delaware 001-38701 26-2216351 (State or other jurisdiction of incorporation or organization) (Commis |
|
| May 4, 2021 |
Offer Letter Agreement, dated April 19, 2021, between the Registrant and Helen Loh Exhibit 10.2 VIA ELECTRONIC DELIVERY April 19, 2021 Re: SI-BONE, Inc. Board of Directors Dear Helen: It is my sincere pleasure to invite you to join the Board of Directors (the ?Board?) of SI-BONE, Inc. (the ?Company?), effective April 19, 2021. As a Board member, you will participate in regularly scheduled and special Board meetings, as well as meetings of any committees that you join; meet or ot |
|
| May 4, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark one) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38701 SI-BONE, |
|
| May 4, 2021 |
Offer Letter Agreement, dated March 4, 2021, between the Registrant and Mika Nishimura Exhibit 10.3 VIA ELECTRONIC DELIVERY March 4, 2021 Re: SI-BONE, Inc. Board of Directors Dear Mika: It is my sincere pleasure to invite you to join the Board of Directors (the ?Board?) of SI-BONE, Inc. (the ?Company?), contingent upon Board approval and effective on March 4, 2021. As a Board member, you will participate in regularly scheduled and special Board meetings, as well as meetings of any c |
|
| May 3, 2021 |
SI-BONE, Inc. Reports First Quarter 2021 Financial Results and Reiterates 2021 Financial Guidance Exhibit 99.1 SI-BONE, Inc. Reports First Quarter 2021 Financial Results and Reiterates 2021 Financial Guidance SANTA CLARA, Calif. May 3, 2021 - SI-BONE, Inc. (Nasdaq:SIBN), a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, today reported financial results for the quarter ended March 31, 2021. Recent Highlights ?Worldwide revenue of $20.4 million f |
|
| May 3, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 3, 2021 SI-BONE, INC. (Exact name of registrant as specified in its charter) Delaware 001-38701 26-2216351 (State or other jurisdiction of incorporation or organization) (Commissi |
|
| April 26, 2021 |
SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| April 26, 2021 |
SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| April 20, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): April 18, 2021 SI-BONE, INC. (Exact name of registrant as specified in its charter) Delaware 001-38701 26-2216351 (State or other jurisdiction of incorporation or organization) (Commi |
|
| April 20, 2021 |
Exhibit 10.2 Amended and Restated Participation Agreement Name: Laura A. Francis Section 1. ELIGIBILITY. You have been designated as eligible to participate in the SI-BONE, Inc. Severance Benefit Plan (the ?Plan?), a copy of which is attached to this Participation Agreement (the ?Participation Agreement?). Capitalized terms not explicitly defined in this Participation Agreement but defined in the |
|
| April 20, 2021 |
Offer Letter Agreement, dated April 20, 2021, between the Registrant and Anshul Maheshwari 471 El Camino Real, Suite 101 Santa Clara, CA 95050 Exhibit 10.1 April 12, 2021 Anshul Maheshwari RE: Employment Offer Dear Anshul: We are pleased to offer you the position of Chief Financial Officer (CFO) with SI-BONE, Inc. (?SI-BONE? or the ?Company?). We believe that your knowledge, skills and experience will be an asset to the Company and that this position will offer a mutually beneficial opp |
|
| March 25, 2021 |
VIA EDGAR March 25, 2021 United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N. |
|
| March 23, 2021 |
SI-BONE, Inc. 471 El Camino Real, Suite 101 Santa Clara, California 95050 VIA EDGAR March 23, 2021 United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: SI-BONE, Inc. Request to Withdraw Registration Statement on Form S-3 Registration No. 333-254214 Ladies and Gentlemen: SI-BONE, Inc. (the ?Company?) hereby requests withdrawa |
|
| March 18, 2021 |
VIA EDGAR March 18, 2021 United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N. |
|
| March 12, 2021 |
As filed with the Securities and Exchange Commission on March 12, 2021 Registration No. |
|
| March 10, 2021 |
As filed with the Securities and Exchange Commission on March 10, 2021 Registration No. |
|
| March 10, 2021 |
2020 Non-Employee Directors' Compensation Policy Exhibit 10.22 SI-BONE, INC. 2020 NON-EMPLOYEE DIRECTORS? COMPENSATION POLICY APPROVED BY THE BOARD OF DIRECTORS December 3, 2020 Each member of the Board of Directors (the ?Board?) who is not also serving as an employee of SI-BONE, Inc. (the ?Company?) or any of its subsidiaries (each such member, an ?Eligible Director?) will receive the compensation described in this Non-Employee Directors? Compe |
|
| March 10, 2021 |
As filed with the U.S. Securities and Exchange Commission on March 10, 2021 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 SI-BONE, Inc. (Exact name of Registrant as specified in its charter) Delaware 26-2216351 (State or other jurisdiction of Incorporation or organization) (I.R.S. Emplo |
|
| March 10, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-38701 SI-BONE, Inc. ( |
|
| March 10, 2021 |
SI-BONE, Inc. Severance Benefit Plan and Form of Participation Agreement Exhibit 10.24 SI-BONE, Inc. Severance Benefit Plan Section 1. INTRODUCTION. The SI-BONE, Inc. Severance Benefit Plan (the ?Plan?) is hereby established by the Compensation Committee of the Board of Directors of SI-BONE, Inc. (the ?Company?) effective July 16, 2020. The purpose of the Plan is to provide for the payment of severance benefits to eligible employees of the Company in the event that suc |
|
| March 10, 2021 |
List of Subsidiaries of Registrant Exhibit 21.1 List of subsidiaries of the Registrant Subsidiary Jurisdiction SI-BONE S.R.L. Italy SI-BONE Deutschland GmbH Germany SI-BONE UK LTD United Kingdom |
|
| March 10, 2021 |
CONFIDENTIAL & PROPRIETARY Exhibit 10.16 ADDENDUM NO. 2 TO MANUFACTURING, QUALITY AND SUPPLY AGREEMENT THIS ADDENDUM NO. 2 TO MANUFACTURING, QUALITY AND SUPPLY AGREEMENT (?Addendum No. 2?), effective as of July 1, 2020 (?Addendum Effective Date?) is by and between SI-BONE, Inc., a Delaware corporation having a principal place of business at 471 El Camino Real, Suite 101, Santa Clara, California 95 |
|
| March 8, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 4, 2021 SI-BONE, INC. (Exact name of registrant as specified in its charter) Delaware 001-38701 26-2216351 (State or other jurisdiction of incorporation or organization) (Commis |
|
| March 8, 2021 |
Exhibit 99.1 SI-BONE, Inc. Reports Fourth Quarter and Full Year 2020 Financial Results and Issues 2021 Financial Guidance SANTA CLARA, Calif. March 8, 2021 - SI-BONE, Inc. (Nasdaq:SIBN), a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, today reported financial results for the quarter and full year ended December 31, 2020. Recent Highlights •Worldw |
|
| February 22, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1 (b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2 (b) (Amendment No. 1)* SI-Bone, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 825704109 (CUSIP Number) December 31, |
|
| January 7, 2021 |
Exhibit 99.1 SI-BONE Announces Senior Leadership Changes and Record Quarterly Revenue Laura Francis to Become Chief Executive Officer; Jeff Dunn to Become Executive Chairman; and Tony Recupero to Become President. SANTA CLARA, Calif., January 7, 2021 – SI-BONE, Inc. (Nasdaq: SIBN) (“SI-BONE” or the “Company”), a Silicon Valley-based medical device company focused on the development of implantable |
|
| January 7, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 5, 2021 SI-BONE, INC. (Exact name of registrant as specified in its charter) Delaware 001-38701 26-2216351 (State or other jurisdiction of incorporation or organization) (Comm |
|
| January 7, 2021 |
si-bonecorporatedeckxjpm 1 Corporate Overview January 2021 v.08032020 Safe Harbor Statement This presentation contains “forward-looking statements,” which are statements related to events, results, activities or developments that SI-BONE expects, believes or anticipates will or may occur in the future. Forward-looking often contain words such as “intends,” “estimates,” “anticipates,” “hopes,” “pro |
|
| January 7, 2021 |
Amendment to Offer Letter with Jeffrey Dunn AMENDMENT TO OFFER LETTER AGREEMENT AND SEVERANCE PLAN PARTICIPATION AGREEMENT This Amendment (this “Amendment”) to the Offer Letter Agreement by and between SI-BONE, Inc. |
|
| November 3, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark one) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38701 SI-BO |
|
| November 2, 2020 |
SI-BONE, Inc. Reports Third Quarter 2020 Financial Results and 2020 Revenue Guidance EX-99.1 2 exhibit991sibn9302020e.htm EX-99.1 Q3 2020 EARNINGS RELEASE Exhibit 99.1 SI-BONE, Inc. Reports Third Quarter 2020 Financial Results and 2020 Revenue Guidance SANTA CLARA, Calif. November 2, 2020 - SI-BONE, Inc. (Nasdaq:SIBN), a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, today reported financial results for the quarter ended September |
|
| November 2, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 2, 2020 SI-BONE, INC. (Exact name of registrant as specified in its charter) Delaware 001-38701 26-2216351 (State or other jurisdiction of incorporation or organization) (Com |
|
| October 16, 2020 |
Financial Statements and Exhibits, Other Events - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): October 14, 2020 SI-BONE, INC. (Exact name of registrant as specified in its charter) Delaware 001-38701 26-2216351 (State or other jurisdiction of incorporation or organization) (Com |
|
| October 16, 2020 |
Prospectus Supplement (To Prospectus dated January 2, 2020) 3,190,053 Shares Common Stock Filed Pursuant to Rule 424(b)(5) Registration No. 333-235714 Prospectus Supplement (To Prospectus dated January 2, 2020) 3,190,053 Shares Common Stock We are offering 3,000,000 shares of our common stock, and the selling stockholder named in this prospectus supplement is offering 190,053 shares of our common stock. Our common stock is listed on the Nasdaq Global Market under the symbol “SIBN.” On |
|
| October 16, 2020 |
Underwriting Agreement, dated October 14, 2020 Exhibit 1.1 Execution Version 3,190,053 Shares SI-BONE, INC. COMMON STOCK (PAR VALUE $0.0001 PER SHARE) UNDERWRITING AGREEMENT October 14, 2020 October 14, 2020 Morgan Stanley & Co. LLC BofA Securities, Inc. c/o Morgan Stanley & Co. LLC 1585 Broadway New York, New York 10036 c/o BofA Securities, Inc. One Bryant Park New York, New York 10036 Ladies and Gentlemen: SI‑BONE, Inc., a Delaware corporati |
|
| October 14, 2020 |
Filed Pursuant to Rule 424(b)(5) Registration No. 333-235714 The information in this preliminary prospectus supplement is not complete and may be changed. A registration statement relating to these securities has been declared effective by the Securities and Exchange Commission. This preliminary prospectus supplement and accompanying prospectus are not an offer to sell these securities, and we and |
|
| October 8, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): October 8, 2020 SI-BONE, INC. (Exact name of registrant as specified in its charter) Delaware 001-38701 26-2216351 (State or other jurisdiction of incorporation or organization) (Comm |
|
| October 8, 2020 |
Exhibit 99.1 SI-BONE Reports Preliminary Unaudited Revenue for the Third Quarter 2020 and Provides Full Year 2020 Revenue Guidance SANTA CLARA, Calif. October 8, 2020 - SI-BONE, Inc. (Nasdaq:SIBN), a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, today announced preliminary unaudited revenue for the three and nine months ended September 30, 2020. |
|
| August 4, 2020 |
EXHIBIT 10.1 LOAN AND SECURITY AGREEMENT THIS LOAN AND SECURITY AGREEMENT (as the same may be amended, restated, modified, or supplemented from time to time, this “Agreement”) dated as of May 29, 2020 (the “Effective Date”) among Solar Capital Ltd., a Maryland corporation, with an office located at 500 Park Avenue, 3rd Floor, New York, NY 10022 (“Solar”), as collateral agent (in such capacity, tog |
|
| August 4, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark one) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38701 SI-BONE, I |
|
| August 3, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 3, 2020 SI-BONE, INC. (Exact name of registrant as specified in its charter) Delaware 001-38701 26-2216351 (State or other jurisdiction of incorporation or organization) (Commi |
|
| August 3, 2020 |
SI-BONE, Inc. Reports Second Quarter 2020 Financial Results Exhibit 99.1 SI-BONE, Inc. Reports Second Quarter 2020 Financial Results SANTA CLARA, Calif. August 3, 2020 - SI-BONE, Inc. (Nasdaq:SIBN), a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, today reported financial results for the quarter ended June 30, 2020. Recent Highlights •Revenue of $14.0 million for the second quarter 2020, representing a 14% |
|
| July 17, 2020 |
SI-BONE, Inc. Severance Benefit Plan and Form of Participation Agreement Exhibit 10.1 SI-BONE, Inc. Severance Benefit Plan Section 1. INTRODUCTION. The SI-BONE, Inc. Severance Benefit Plan (the “Plan”) is hereby established by the Compensation Committee of the Board of Directors of SI-BONE, Inc. (the “Company”) effective July 16, 2020. The purpose of the Plan is to provide for the payment of severance benefits to eligible employees of the Company in the event that such |
|
| July 17, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 16, 2020 SI-BONE, INC. (Exact name of registrant as specified in its charter) Delaware 001-38701 26-2216351 (State or other jurisdiction of incorporation or organization) (Commis |
|
| July 1, 2020 |
SIBN / SI-BONE, Inc. / INTEGRATED CORE STRATEGIES (US) LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 SI-BONE, INC. (Name of Issuer) COMMON STOCK, PAR VALUE $0.0001 PER SHARE (Title of Class of Securities) 825704109 (CUSIP Number) JUNE 25, 2020 (Date of event which requires filing of this statement) Check the appropriate box to designate the rule pursuant to which this Sch |
|
| June 17, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q/A (Amendment No. 1) (Mark one) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: |
|
| June 17, 2020 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 16, 2020 SI-BONE, INC. (Exact name of registrant as specified in its charter) Delaware 001-38701 26-2216351 (State or other jurisdiction of incorporation or organization) (Commis |
|
| June 17, 2020 |
SI-BONE, Inc. 471 El Camino Real, Suite 101 Santa Clara, California 95050 June 17, 2020 Via Email and Edgar U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Mail Stop 3720 Washington, D.C. 20549 Attn: Kevin Kuhar, Accounting Branch Chief Re: SI-BONE, Inc. Form 10-K for the Fiscal Year Ended December 31, 2019 Filed March 11, 2020 Form 10-Q for the Fiscal Qu |
|
| June 1, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 29, 2020 SI-BONE, INC. (Exact name of registrant as specified in its charter) Delaware 001-38701 26-2216351 (State or other jurisdiction of incorporation or organization) (Commiss |
|
| May 27, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant þ Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ¨ Defin |
|
| May 5, 2020 |
Description of SI-BONE, Inc. Common Stock Exhibit 4.3 DESCRIPTION OF SI-BONE, INC. COMMON STOCK Our authorized capital stock consists of 100,000,000 shares of common stock, $0.0001 par value per share, and 5,000,000 shares of preferred stock, $0.0001 par value per share. A description of our common stock and the material terms and provisions of our certificate of incorporation and bylaws affecting the rights of holders of our common stock |
|
| May 5, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark one) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38701 SI-BONE, |
|
| May 4, 2020 |
SI-BONE, Inc. Reports First Quarter 2020 Financial Results Exhibit 99.1 SI-BONE, Inc. Reports First Quarter 2020 Financial Results SANTA CLARA, Calif. May 4, 2020 - SI-BONE, Inc. (Nasdaq:SIBN), a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, today reported financial results for the quarter ended March 31, 2020. Recent Highlights •Revenue of $16.8 million for the first quarter 2020, representing a 12% inc |
|
| May 4, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 4, 2020 SI-BONE, INC. (Exact name of registrant as specified in its charter) Delaware 001-38701 26-2216351 (State or other jurisdiction of incorporation or organization) (Commissi |
|
| April 22, 2020 |
Definitive Proxy Statement on Schedule 14A, filed on April 22, 2020 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| April 2, 2020 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): April 2, 2020 SI-BONE, INC. (Exact name of registrant as specified in its charter) Delaware 001-38701 26-2216351 (State or other jurisdiction of incorporation or organization) (Commis |
|
| April 2, 2020 |
SI-BONE, Inc. Provides Business Update in Response to COVID-19 Pandemic Exhibit 99.1 SI-BONE, Inc. Provides Business Update in Response to COVID-19 Pandemic SANTA CLARA, Calif. April 2, 2020 - SI-BONE, Inc. (Nasdaq:SIBN), a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, today provided an update on the actions it is taking to support patients, customers, and employees while maintaining business continuity in response t |
|
| March 30, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 26, 2020 SI-BONE, INC. (Exact name of registrant as specified in its charter) Delaware 001-38701 26-2216351 (State or other jurisdiction of incorporation or organization) (Commi |
|
| March 11, 2020 |
2019 Non-Employee Directors' Compensation Policy Exhibit 10.36 SI-BONE, Inc. 2019 Non-Employee Directors’ Compensation Policy Approved by the Board of Directors June 13, 2019 Each member of the Board of Directors (the “Board”) who is not also serving as an employee of SI-BONE, Inc. (the “Company”) or any of its subsidiaries (each such member, an “Eligible Director”) will receive the compensation described in this Non-Employee Directors’ Compensa |
|
| March 11, 2020 |
SIBN / SI-BONE, Inc. S-8 - - S-8 As filed with the U.S. Securities and Exchange Commission on March 11, 2020 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 SI-BONE, Inc. (Exact name of Registrant as specified in its charter) Delaware 26-2216351 (State or other jurisdiction of Incorporation or organization) (I.R.S. Emplo |
|
| March 11, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10‑K (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001‑38701 SI-BONE, Inc. ( |
|
| March 11, 2020 |
List of Subsidiaries of Registrant Exhibit 21.1 List of subsidiaries of the Registrant Subsidiary Jurisdiction SI-BONE S.R.L. Italy SI-BONE Deutschland GmbH Germany SI-BONE UK LTD United Kingdom |
|
| March 11, 2020 |
Description of SI-BONE, Inc. Common Stock Exhibit 4.3 DESCRIPTION OF SI-BONE, INC. COMMON STOCK Our authorized capital stock consists of 100,000,000 shares of common stock, $0.0001 par value per share, and 5,000,000 shares of preferred stock, $0.0001 par value per share. A description of our common stock and the material terms and provisions of our certificate of incorporation and bylaws affecting the rights of holders of our common stock |
|
| March 10, 2020 |
SIBN / SI-BONE, Inc. / MONTREUX EQUITY PARTNERS IV LP - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* SI-BONE, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 825704 10 9 (CUSIP Number) January 27, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule |
|
| March 9, 2020 |
Exhibit 99.1 SI-BONE, Inc. Reports Fourth Quarter and Full Year 2019 Financial Results Reiterates Full Year 2020 Financial Outlook SANTA CLARA, Calif. March 9, 2020 - SI-BONE, Inc. (Nasdaq:SIBN), a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, today reported financial results for the quarter and full year ended December 31, 2019. Recent Highlight |
|
| March 9, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 9, 2020 SI-BONE, INC. (Exact name of registrant as specified in its charter) Delaware 001-38701 26-2216351 (State or other jurisdiction of incorporation or organization) (Commis |
|
| February 14, 2020 |
Joint Filing Statement Pursuant to Rule 13d-1(k)(1) Exhibit 1 Joint Filing Statement Pursuant to Rule 13d-1(k)(1) The undersigned hereby consent and agree to the joint filing of Schedule 13G Amendment No. |
|
| February 14, 2020 |
SIBN / SI-BONE, Inc. / RTW INVESTMENTS, LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| February 12, 2020 |
Exhibit 99.1 CUSIP No. 825704109 AGREEMENT Pursuant to Rule 13d-1(k)(l) promulgated pursuant to the Securities Exchange Act of 1934, as amended, the undersigned agree that the attached Schedule 13G is being filed on behalf of each of the undersigned. February 12, 2020 SKYLINE VENTURE PARTNERS V, L.P. BY: SKYLINE VENTURE MANAGEMENT V, LLC ITS: GENERAL PARTNER By: /s/ Kerensa Kenny as attorney-in-fa |
|
| February 12, 2020 |
SIBN / SI-BONE, Inc. / Skyline Venture Partners V LP - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1 (b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2 (b) (Amendment No. 1)* SI-BONE, INC. (Name of Issuer) COMMON STOCK, PAR VALUE $0.0001 PER SHARE (Title of Class of Securities) 825704109 (CUSIP Number) DECEMBER 31, |
|
| January 24, 2020 |
Underwriting Agreement, dated January 22, 2020 Exhibit 1.1 Execution Version 4,300,000 Shares SI‑BONE, INC. COMMON STOCK (PAR VALUE $0.0001 PER SHARE) UNDERWRITING AGREEMENT January 22, 2020 January 22, 2020 Morgan Stanley & Co. LLC BofA Securities, Inc. c/o Morgan Stanley & Co. LLC 1585 Broadway New York, New York 10036 c/o BofA Securities, Inc. One Bryant Park New York, New York 10036 Ladies and Gentlemen: SI‑BONE, Inc., a Delaware corporati |
|
| January 24, 2020 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 22, 2020 SI-BONE, INC. (Exact name of registrant as specified in its charter) Delaware 001-38701 26-2216351 (State or other jurisdiction of incorporation or organization) (Com |
|
| January 23, 2020 |
Prospectus Supplement (To Prospectus dated January 2, 2020) 4,300,000 Shares Common Stock Filed Pursuant to Rule 424(b)(5) Registration No. 333-235714 Prospectus Supplement (To Prospectus dated January 2, 2020) 4,300,000 Shares Common Stock We are offering 2,490,053 shares of our common stock, and the selling stockholders named in this prospectus supplement are offering 1,809,947 shares of our common stock. Our common stock is listed on the Nasdaq Global Market under the symbol “SIBN.” |
|
| January 21, 2020 |
SIBN / SI-BONE, Inc. SUPPL - - PROSPECTUS SUPPLEMENT The information in this preliminary prospectus supplement is not complete and may be changed. |
|
| January 21, 2020 |
Filed Pursuant to Rule 424(b)(5) Registration No. 333-235714 The information in this preliminary prospectus supplement is not complete and may be changed. A registration statement relating to these securities has been declared effective by the Securities and Exchange Commission is effective. This preliminary prospectus supplement and accompanying prospectus are not an offer to sell these securitie |
|
| January 9, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 9, 2020 SI-BONE, INC. (Exact name of registrant as specified in its charter) Delaware 001-38701 26-2216351 (State or other jurisdiction of incorporation or organization) (Comm |
|
| January 9, 2020 |
sibonecorporatepresentat Exhibit 99.2 Corporate Overview January 2020 1 Safe Harbor Statement This presentation contains “forward-looking statements,” which are statements related to future events, expectations, results, activities, events or developments that SI-BONE expects, believes or anticipates will or may occur in the future. Forward-looking often contain words such as “intends,” “estimates |
|
| January 9, 2020 |
EX-99.1 2 q42019pre-annoucementrelea.htm EXHIBIT 99.1 Exhibit 99.1 SI-BONE Reports Preliminary Unaudited Revenue for Fourth Quarter and Full Year 2019 and Provides Full Year 2020 Revenue Guidance SANTA CLARA, Calif. - January 9, 2019 - SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, today announced preliminary unaudi |
|
| January 3, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 3, 2020 SI-BONE, INC. (Exact name of registrant as specified in its charter) Delaware 001-38701 26-2216351 (State or other jurisdiction of incorporation or organization) (Comm |
|
| December 30, 2019 |
SIBN / SI-BONE, Inc. CORRESP - - SI-BONE, Inc. 471 El Camino Real, Suite 101 Santa Clara, California 95050 December 30, 2019 Via Email and Edgar U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Mail Stop 3720 Washington, D.C. 20549 Attn: Irene Paik RE: SI-BONE, Inc. Registration Statement on Form S-3 File No. 333-235714 Ladies and Gentlemen: SI-BONE, Inc. (the “Registrant”) hereby request |
|
| December 27, 2019 |
SIBN / SI-BONE, Inc. S-3 - - S-3 As filed with the Securities and Exchange Commission on December 26, 2019 Registration No. |
|
| December 4, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): December 3, 2019 SI-BONE, INC. (Exact name of registrant as specified in its charter) Delaware 001-38701 26-2216351 (State or other jurisdiction of incorporation or organization) (Com |
|
| November 21, 2019 |
SIBN / SI-BONE, Inc. CORRESP - - SI-BONE, Inc. 471 El Camino Real, Suite 101 Santa Clara, California 95050 November 21, 2019 Via Email and Edgar U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Mail Stop 3720 Washington, D.C. 20549 Attn: Jeffrey Gabor RE: SI-BONE, Inc. Registration Statement on Form S-3 File No. 333-234679 Ladies and Gentlemen: SI-BONE, Inc. (the “Registrant”) hereby requ |
|
| November 13, 2019 |
Exhibit 4.4 SI-BONE, INC, Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of [•], 20 Debt Securities TABLE OF CONTENTS PAGE ARTICLE 1 DEFINITIONS Section 1.01 Definitions of Terms 1 ARTICLE 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES Section 2.01 Designation and Terms of Securities 4 Section 2.02 Form of Securities and Trustee’s Certificate 6 Section 2.03 Denom |
|
| November 13, 2019 |
Form of Debt Securities Warrant Agreement and Warrant Certificate Exhibit 4.8 SI-BONE, INC. AND , AS WARRANT AGENT FORM OF DEBT SECURITIES WARRANT AGREEMENT DATED AS OF SI-BONE, INC. FORM OF DEBT SECURITIES WARRANT AGREEMENT THIS DEBT SECURITIES WARRANT AGREEMENT (this “Agreement”), dated as of [●], between SI-BONE, INC., a Delaware corporation (the “Company”) and [●], a [corporation] [national banking association] organized and existing under the laws of [●] an |
|
| November 13, 2019 |
Form of Preferred Stock Warrant Agreement and Warrant Certificate Exhibit 4.7 SI-BONE, INC. AND , AS WARRANT AGENT FORM OF PREFERRED STOCK WARRANT AGREEMENT DATED AS OF SI-BONE, INC. FORM OF PREFERRED STOCK WARRANT AGREEMENT THIS PREFERRED STOCK WARRANT AGREEMENT (this “Agreement”), dated as of [●], between SI-BONE, INC., a Delaware corporation (the “Company”) and [●], a [corporation] [national banking association] organized and existing under the laws of [●] an |
|
| November 13, 2019 |
SIBN / SI-BONE, Inc. S-3 - - S-3 As filed with the Securities and Exchange Commission on November 13, 2019 Registration No. |
|
| November 13, 2019 |
Form of Common Stock Warrant Agreement and Warrant Certificate Exhibit 4.6 SI-BONE, INC. AND , AS WARRANT AGENT FORM OF COMMON STOCK WARRANT AGREEMENT DATED AS OF SI-BONE, INC. FORM OF COMMON STOCK WARRANT AGREEMENT THIS COMMON STOCK WARRANT AGREEMENT (this “Agreement”), dated as of [●], between, SI-BONE, INC., a Delaware corporation (the “Company”) and [●], a [corporation] [national banking association] organized and existing under the laws of [●] and having |
|
| November 12, 2019 |
SIBN / SI-BONE, Inc. 10-Q - Quarterly Report - 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark one) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2019 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38701 SI-BO |
|
| November 12, 2019 |
Amendment to Restricted Stock Units of Laura Francis exhibit102amendmenttores DocuSign Envelope ID: 996D5718-E3CE-4796-8706-C8A63C6557E9 SI-BONE, INC. |
|
| November 12, 2019 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 11, 2019 SI-BONE, INC. (Exact name of registrant as specified in its charter) Delaware 001-38701 26-2216351 (State or other jurisdiction of incorporation or organization) (Co |
|
| November 12, 2019 |
Exhibit 99.1 SI-BONE, Inc. Reports Third Quarter 2019 Financial Results and Updates Full-Year 2019 Revenue Guidance SANTA CLARA, Calif. November 11, 2019 - SI-BONE, Inc. (Nasdaq:SIBN), a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, today reported financial results for the quarter ended September 30, 2019. Recent Highlights • Revenue of $16.2 mil |
|
| August 14, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 13, 2019 SI-BONE, INC. (Exact name of registrant as specified in its charter) Delaware 001-38701 26-2216351 (State or other jurisdiction of incorporation or organization) (Comm |
|
| August 7, 2019 |
SIBN / SI-BONE, Inc. 10-Q - Quarterly Report - 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark one) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2019 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38701 SI-BONE, I |
|
| August 6, 2019 |
SI-BONE, Inc. Reports Second Quarter 2019 Financial Results Exhibit 99.1 SI-BONE, Inc. Reports Second Quarter 2019 Financial Results SANTA CLARA, Calif. August 6, 2019 - SI-BONE, Inc. (Nasdaq:SIBN), a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, today reported financial results for the quarter ended June 30, 2019. Recent Highlights • Revenue of $16.3 million for the second quarter 2019, representing a 19 |
|
| August 6, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 24, 2019 SI-BONE, INC. (Exact name of registrant as specified in its charter) Delaware 001-38701 26-2216351 (State or other jurisdiction of incorporation or organization) (Commis |
|
| June 14, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 10, 2019 SI-BONE, INC. (Exact name of registrant as specified in its charter) Delaware 001-38701 26-2216351 (State or other jurisdiction of incorporation or organization) (Commis |
|
| May 9, 2019 |
SIBN / SI-BONE, Inc. 10-Q Quarterly Report 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark one) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2019 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38701 SI-BONE, |
|
| May 8, 2019 |
SI-BONE, Inc. Reports First Quarter 2019 Financial Results Exhibit 99.1 SI-BONE, Inc. Reports First Quarter 2019 Financial Results SANTA CLARA, Calif. May 8, 2019 - SI-BONE, Inc. (Nasdaq:SIBN), a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, today reported financial results for the quarter ended March 31, 2019. Recent Highlights • Revenues of $15.0 million for the first quarter of 2019, representing an 1 |
|
| May 8, 2019 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 8, 2019 SI-BONE, INC. (Exact name of registrant as specified in its charter) Delaware 001-38701 26-2216351 (State or other jurisdiction of incorporation or organization) (Commissi |
|
| April 30, 2019 |
Definitive Proxy Statement on Schedule 14A, filed on April 30, 2019 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
